Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:LKFT NASDAQ:NVCT NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$27.28-1.3%$24.43$11.32▼$31.00$1.87B1.28268,314 shs163,864 shsLKFTLakefront Biotherapeutics American Depositary Shares$27.84-1.0%$28.75$26.42▼$37.78$1.83B0.25153,710 shs167,206 shsNVCTNuvectis Pharma$19.31-4.2%$15.38$5.55▼$29.27$512.22M-0.24525,979 shs248,222 shsOCULOcular Therapeutix$8.51-1.3%$9.12$6.23▼$16.44$1.86B0.882.30 million shs1.17 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research0.00%-4.98%+7.66%+34.72%+91.57%LKFTLakefront Biotherapeutics American Depositary Shares0.00%-7.23%-3.47%-2.66%-16.37%NVCTNuvectis Pharma0.00%+0.89%-30.71%+116.97%+145.67%OCULOcular Therapeutix0.00%-5.13%-12.81%-10.33%-28.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$27.28-1.3%$24.43$11.32▼$31.00$1.87B1.28268,314 shs163,864 shsLKFTLakefront Biotherapeutics American Depositary Shares$27.84-1.0%$28.75$26.42▼$37.78$1.83B0.25153,710 shs167,206 shsNVCTNuvectis Pharma$19.31-4.2%$15.38$5.55▼$29.27$512.22M-0.24525,979 shs248,222 shsOCULOcular Therapeutix$8.51-1.3%$9.12$6.23▼$16.44$1.86B0.882.30 million shs1.17 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research0.00%-4.98%+7.66%+34.72%+91.57%LKFTLakefront Biotherapeutics American Depositary Shares0.00%-7.23%-3.47%-2.66%-16.37%NVCTNuvectis Pharma0.00%+0.89%-30.71%+116.97%+145.67%OCULOcular Therapeutix0.00%-5.13%-12.81%-10.33%-28.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 2.64Moderate Buy$40.3848.00% UpsideLKFTLakefront Biotherapeutics American Depositary Shares 2.11Hold$34.3323.32% UpsideNVCTNuvectis Pharma 2.33Hold$35.0081.25% UpsideOCULOcular Therapeutix 2.71Moderate Buy$25.11195.08% UpsideCurrent Analyst Ratings BreakdownLatest NVCT, LKFT, OCUL, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026GHRSGH Research Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/14/2026OCULOcular Therapeutix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/10/2026LKFTLakefront Biotherapeutics American Depositary Shares Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$30.007/6/2026NVCTNuvectis Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.007/6/2026NVCTNuvectis Pharma Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $33.006/25/2026OCULOcular Therapeutix Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $23.006/22/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $39.006/18/2026OCULOcular Therapeutix Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $30.006/18/2026OCULOcular Therapeutix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.00 ➝ $25.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/ALKFTLakefront Biotherapeutics American Depositary Shares$1.26B1.46$0.73 per share38.34$47.57 per share0.59NVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/AOCULOcular Therapeutix$51.95M35.87N/AN/A$3.07 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)LKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)NVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)Latest NVCT, LKFT, OCUL, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026LKFTLakefront Biotherapeutics American Depositary Shares-$0.9672N/AN/AN/A$7.29 millionN/A8/6/2026Q2 2026GHRSGH Research-$0.31N/AN/AN/AN/AN/A8/4/2026Q2 2026NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A8/4/2026Q2 2026OCULOcular Therapeutix-$0.40N/AN/AN/A$13.20 millionN/A5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$8.75 million5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/ALKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A34.1334.13LKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30NVCTNuvectis PharmaN/A2.272.27OCULOcular Therapeutix0.1214.8114.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%LKFTLakefront Biotherapeutics American Depositary Shares32.46%NVCTNuvectis Pharma96.77%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%LKFTLakefront Biotherapeutics American Depositary Shares2.91%NVCTNuvectis Pharma28.55%OCULOcular Therapeutix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1068.61 million40.07 millionOptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionableNVCTNuvectis Pharma826.53 million18.95 millionNot OptionableOCULOcular Therapeutix230218.96 million212.17 millionOptionableNVCT, LKFT, OCUL, and GHRS HeadlinesRecent News About These CompaniesIs Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?July 24 at 9:43 AM | uk.finance.yahoo.comOcular Therapeutix Eyes Q4 AXPAXLI NDA After FDA AlignmentJuly 22, 2026 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 10.6% - Here's WhyJuly 16, 2026 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Rating Lowered to Strong Sell at Zacks ResearchJuly 16, 2026 | marketbeat.comY Intercept Hong Kong Ltd Sells 340,632 Shares of Ocular Therapeutix, Inc. $OCULJuly 15, 2026 | marketbeat.comCandriam S.C.A. Raises Position in Ocular Therapeutix, Inc. $OCULJuly 13, 2026 | marketbeat.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 9, 2026 | globenewswire.comOcular Therapeutix Inc.July 7, 2026 | barrons.comOcular Therapeutix™ to Participate in July Scientific and Investor ConferencesJuly 1, 2026 | globenewswire.comSummer Road LLC Has $100.62 Million Stock Holdings in Ocular Therapeutix, Inc. $OCULJuly 1, 2026 | marketbeat.comOcular Therapeutix (OCUL): Buy, sell, or hold post Q1 earnings?June 24, 2026 | msn.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 22, 2026 | globenewswire.comOcular Therapeutix, Inc. (OCUL) Analyst/Investor Day - SlideshowJune 17, 2026 | seekingalpha.comOCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?June 17, 2026 | finance.yahoo.comWhy Ocular Therapeutix (OCUL) stock is up todayJune 17, 2026 | msn.comOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026June 17, 2026 | globenewswire.comOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?June 15, 2026 | fool.comAssessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price VolatilityJune 6, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comOcular Therapeutix, Inc. to Participate in Clinical Trials at the Summit 2026 in Las VegasJune 4, 2026 | quiverquant.comQOcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026June 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCT, LKFT, OCUL, and GHRS Company DescriptionsGH Research NASDAQ:GHRS$27.28 -0.35 (-1.27%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$26.44 -0.85 (-3.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$27.84 -0.28 (-1.00%) As of 07/24/2026 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Nuvectis Pharma NASDAQ:NVCT$19.31 -0.84 (-4.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.20 -0.11 (-0.54%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Ocular Therapeutix NASDAQ:OCUL$8.51 -0.11 (-1.28%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.44 -0.07 (-0.86%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
